Get your free personalized podcast brief
We scan new podcasts and send you the top 5 insights daily.
A key advancement in federated learning for drug discovery abandons forced data standardization. New two-pronged models are trained on each company's unique, heterogeneous data locally, then pass generalized learnings to a central model, finally overcoming the long-standing interoperability hurdle.
Related Insights
A significant part of Unlearn.ai's value is not just its advanced generative models, but its painstaking data harmonization work. The company builds internal machine learning tools to unify complex, disparate data sources like clinical trials and real-world data, which is the essential foundation for creating powerful models.
Many pharma companies chase advanced AI without solving the foundational challenge of data integration. With only 10% of firms having unified data, true personalization is impossible until a central data platform is established to break down the typical 100+ data silos.
Electronic Health Record (EHR) companies have historically used proprietary formats to lock in customers. AI's ability to read and translate unstructured data from any source effectively breaks these data silos, finally making patient data truly portable.
Chai Discovery's partnership with Eli Lilly involves building a custom foundation model trained on Lilly's unique historical data. This signals a new collaboration model where AI firms act as specialized infrastructure builders, creating proprietary, data-moated AI for large pharmaceutical companies.
Numenos AI found that unifying biological data without traditional borders, such as incorporating mouse data or cancer data for dermatological diseases, surprisingly increases the predictive accuracy of their models. This challenges the siloed approach to traditional research.
To overcome data sovereignty concerns, Altana brings its platform to its clients' data rather than centralizing it. It extracts learnings—like supply chain connections and model improvements—without copying sensitive details like pricing. This federated approach enables a shared intelligence network.
The primary barrier to AI in drug discovery is the lack of large, high-quality training datasets. The emergence of federated learning platforms, which protect raw data while collectively training models, is a critical and undersung development for advancing the field.
The issue with public protein affinity databases isn't just a lack of data, but a lack of interoperability. Data aggregated from different labs using varied methods, buffers, and conditions creates a "messy" dataset that hinders an AI's ability to learn generalizable rules, a problem solved by standardized assays.
Rather than forcing thousands of global hospitals to adopt uniform instruments or protocols, Sophia Genetics' platform is built to work across this complexity. This approach supports wider adoption and turns the challenge of diverse data sources into a strength for building robust, generalizable AI models.
By choosing a partnership model over developing its own drugs, Chai Discovery subjects its AI to a higher bar. Its models must generalize across diverse targets for multiple partners like Pfizer and Eli Lilly, preventing them from creating bespoke solutions for a single problem. This business model forces technical rigor and scalability.
